Linked Data API

Show Search Form

Search Results

1349081
registered interest false more like this
date less than 2021-07-21more like thismore than 2021-07-21
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Human Papillomavirus: Screening more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of introducing mRNA-based human papillomavirus testing for primary cervical screening throughout England. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Rosie Cooper more like this
uin 37400 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2021-09-06more like thismore than 2021-09-06
answer text <p>In November 2015, the United Kingdom National Screening Committee (UK NSC) recommended the use of human papillomavirus (HPV) as the primary screen test for cervical screening, replacing cytology-based screening, as it was more accurate in detecting cervical cancers.</p><p>Laboratories can choose to use either deoxyribonucleic acid (DNA) or messenger ribonucleic acid (mRNA)-based (HPV) testing platforms as both are approved for use in the national cervical screening programme.</p><p>Public Health England assessed the performance of both mRNA and DNA-based HPV testing platforms prior to their implementation in the national cervical screening programme. Both platforms were effective and performed to the level required. The type of HPV platform used does not have an impact on patient experience or effectiveness.</p> more like this
answering member constituency Bury St Edmunds more like this
answering member printed Jo Churchill more like this
grouped question UIN
37401 more like this
37402 more like this
question first answered
less than 2021-09-06T11:23:08.493Zmore like thismore than 2021-09-06T11:23:08.493Z
answering member
4380
label Biography information for Jo Churchill more like this
tabling member
1538
label Biography information for Rosie Cooper more like this
1349082
registered interest false more like this
date less than 2021-07-21more like thismore than 2021-07-21
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Human Papillomavirus: Screening more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what recent assessment his Department has made of the comparative effectiveness of mRNA-based human papillomavirus primary cervical screening offers and DNA-based screening. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Rosie Cooper more like this
uin 37401 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2021-09-06more like thismore than 2021-09-06
answer text <p>In November 2015, the United Kingdom National Screening Committee (UK NSC) recommended the use of human papillomavirus (HPV) as the primary screen test for cervical screening, replacing cytology-based screening, as it was more accurate in detecting cervical cancers.</p><p>Laboratories can choose to use either deoxyribonucleic acid (DNA) or messenger ribonucleic acid (mRNA)-based (HPV) testing platforms as both are approved for use in the national cervical screening programme.</p><p>Public Health England assessed the performance of both mRNA and DNA-based HPV testing platforms prior to their implementation in the national cervical screening programme. Both platforms were effective and performed to the level required. The type of HPV platform used does not have an impact on patient experience or effectiveness.</p> more like this
answering member constituency Bury St Edmunds more like this
answering member printed Jo Churchill more like this
grouped question UIN
37400 more like this
37402 more like this
question first answered
less than 2021-09-06T11:23:08.54Zmore like thismore than 2021-09-06T11:23:08.54Z
answering member
4380
label Biography information for Jo Churchill more like this
tabling member
1538
label Biography information for Rosie Cooper more like this
1349085
registered interest false more like this
date less than 2021-07-21more like thismore than 2021-07-21
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Human Papillomavirus: Screening more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what comparative assessment his Department has made of the effect on patient experience of mRNA-based human papillomavirus testing for primary cervical screening and DNA-based screening. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Rosie Cooper more like this
uin 37402 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2021-09-06more like thismore than 2021-09-06
answer text <p>In November 2015, the United Kingdom National Screening Committee (UK NSC) recommended the use of human papillomavirus (HPV) as the primary screen test for cervical screening, replacing cytology-based screening, as it was more accurate in detecting cervical cancers.</p><p>Laboratories can choose to use either deoxyribonucleic acid (DNA) or messenger ribonucleic acid (mRNA)-based (HPV) testing platforms as both are approved for use in the national cervical screening programme.</p><p>Public Health England assessed the performance of both mRNA and DNA-based HPV testing platforms prior to their implementation in the national cervical screening programme. Both platforms were effective and performed to the level required. The type of HPV platform used does not have an impact on patient experience or effectiveness.</p> more like this
answering member constituency Bury St Edmunds more like this
answering member printed Jo Churchill more like this
grouped question UIN
37400 more like this
37401 more like this
question first answered
less than 2021-09-06T11:23:08.447Zmore like thismore than 2021-09-06T11:23:08.447Z
answering member
4380
label Biography information for Jo Churchill more like this
tabling member
1538
label Biography information for Rosie Cooper more like this
1349089
registered interest false more like this
date less than 2021-07-21more like thismore than 2021-07-21
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Cervical Cancer: Screening more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential merits of using digital cytology for cervical cancer screening programmes on (a) capacity and (b) resource flexibility. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Rosie Cooper more like this
uin 37403 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2021-09-06more like thismore than 2021-09-06
answer text <p>The merits of digital cytology cannot be assessed at this time as the technology is in initial development and not yet ready for commercial use. Once fully developed, NHS England and NHS Improvement will validate whether the technology is suitable for cervical screening samples.</p> more like this
answering member constituency Bury St Edmunds more like this
answering member printed Jo Churchill more like this
question first answered
less than 2021-09-06T11:57:50.4Zmore like thismore than 2021-09-06T11:57:50.4Z
answering member
4380
label Biography information for Jo Churchill more like this
tabling member
1538
label Biography information for Rosie Cooper more like this
1349098
registered interest false more like this
date less than 2021-07-21more like thismore than 2021-07-21
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Antimicrobials more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether his Department plans to re-launch the Joint-Industry Government Working Group on Antimicrobial Resistance; and if he will make a statement. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Rosie Cooper more like this
uin 37404 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2021-09-06more like thismore than 2021-09-06
answer text <p>We will re-launch the Joint Government/Industry Working Group on antimicrobial resistance later this year. The group’s work will include collaboration on the discovery and development of new antimicrobials, in particular with respect to the United Kingdom’s pilot scheme to test an alternative, subscription reimbursement model for use of new antibiotics on the National Health Service.</p> more like this
answering member constituency Bury St Edmunds more like this
answering member printed Jo Churchill more like this
grouped question UIN 37405 more like this
question first answered
less than 2021-09-06T11:59:10.793Zmore like thismore than 2021-09-06T11:59:10.793Z
answering member
4380
label Biography information for Jo Churchill more like this
tabling member
1538
label Biography information for Rosie Cooper more like this
1349100
registered interest false more like this
date less than 2021-07-21more like thismore than 2021-07-21
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Antimicrobials more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, whether he has plans to re-establish a formal Government to industry dialogue on steps to accelerate the discovery and development in anti-microbials; and if he will make a statement. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Rosie Cooper more like this
uin 37405 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2021-09-06more like thismore than 2021-09-06
answer text <p>We will re-launch the Joint Government/Industry Working Group on antimicrobial resistance later this year. The group’s work will include collaboration on the discovery and development of new antimicrobials, in particular with respect to the United Kingdom’s pilot scheme to test an alternative, subscription reimbursement model for use of new antibiotics on the National Health Service.</p> more like this
answering member constituency Bury St Edmunds more like this
answering member printed Jo Churchill more like this
grouped question UIN 37404 more like this
question first answered
less than 2021-09-06T11:59:10.857Zmore like thismore than 2021-09-06T11:59:10.857Z
answering member
4380
label Biography information for Jo Churchill more like this
tabling member
1538
label Biography information for Rosie Cooper more like this
1343607
registered interest false more like this
date less than 2021-07-05more like thismore than 2021-07-05
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Immunosuppression: Coronavirus more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what progress his Department has made on research on the efficacy of (a) monoclonal antibodies and (b) other alternative treatments for immunocompromised and immunosuppressed groups. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Rosie Cooper more like this
uin 27083 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2021-07-13more like thismore than 2021-07-13
answer text <p>The National Institute for Health Research (NIHR) has supported 15 studies on monoclonal antibodies and other therapies for immunocompromised and immunosuppressed groups, including cell therapy and the use of probiotics. Twelve of these studies are now complete and three are ongoing. All NIHR-funded research is expected to be published in peer-reviewed, open access journals once completed to promote translation into patient care where appropriate.</p> more like this
answering member constituency Charnwood more like this
answering member printed Edward Argar more like this
question first answered
less than 2021-07-13T13:56:43.053Zmore like thismore than 2021-07-13T13:56:43.053Z
answering member
4362
label Biography information for Edward Argar more like this
tabling member
1538
label Biography information for Rosie Cooper more like this
1343608
registered interest false more like this
date less than 2021-07-05more like thismore than 2021-07-05
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Coronavirus: Vaccination more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what progress he has made on research into the efficacy of a third booster dose of a covid-19 vaccine for immunocompromised and immunosuppressed groups. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Rosie Cooper more like this
uin 27084 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2021-07-13more like thismore than 2021-07-13
answer text <p>The COV-BOOST study was commissioned through the National Institute for Health Research and will provide vital data on the impact of a third dose on patients’ immune responses. Initial findings are expected in September. To fully understand how COVID-19 vaccines respond as a booster dose they must first be studied in people with a fully functioning immune system.</p><p>UK Research and Innovation is providing £4 million towards the OCTAVE study examining COVID-19 vaccine responses in clinically at-risk groups, including immunocompromised patients.</p> more like this
answering member constituency Stratford-on-Avon more like this
answering member printed Nadhim Zahawi more like this
question first answered
less than 2021-07-13T15:40:44.8Zmore like thismore than 2021-07-13T15:40:44.8Z
answering member
4113
label Biography information for Nadhim Zahawi more like this
tabling member
1538
label Biography information for Rosie Cooper more like this
1343609
registered interest false more like this
date less than 2021-07-05more like thismore than 2021-07-05
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Immunosuppression: Coronavirus more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, what plans he has to help ensure the future protection for people who are (a) immunocompromised and (b) immunosuppressed who may still be at risk from covid-19 despite the vaccine rollout. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Rosie Cooper more like this
uin 27085 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2021-08-26more like thismore than 2021-08-26
answer text <p>Immunocompromised individuals are a priority cohort for research into therapeutic and prophylaxis treatments, such as monoclonal antibody therapies, novel antivirals and repurposed compounds. The National Health Service is also developing plans to deploy monoclonal antibody therapies if these become available in coming months.</p><p>In addition, subject to final advice from the Joint Committee on Vaccination and Immunisation, those most vulnerable to COVID-19 may be offered a booster vaccination. Until these treatments are available, patients with immunosuppression are advised to continue following advice to reduce their chance of exposure.</p> more like this
answering member constituency Bury St Edmunds more like this
answering member printed Jo Churchill more like this
question first answered
less than 2021-08-26T15:09:41.17Zmore like thismore than 2021-08-26T15:09:41.17Z
answering member
4380
label Biography information for Jo Churchill more like this
tabling member
1538
label Biography information for Rosie Cooper more like this
1332293
registered interest false more like this
date less than 2021-06-11more like thismore than 2021-06-11
answering body
Department of Health and Social Care more like this
answering dept id 17 remove filter
answering dept short name Health and Social Care more like this
answering dept sort name Health and Social Care more like this
hansard heading Members: Correspondence more like this
house id 1 more like this
legislature
25259
pref label House of Commons more like this
question text To ask the Secretary of State for Health and Social Care, when he plans to respond to the letter dated 12 February 2021 from the hon. Member for West Lancashire, regarding the CQC report of a Health Care Provider in the North West, ref ZA55567. more like this
tabling member constituency West Lancashire more like this
tabling member printed
Rosie Cooper more like this
uin 14147 more like this
answer
answer
is ministerial correction false more like this
date of answer less than 2021-06-23more like thismore than 2021-06-23
answer text <p>We replied to the hon. Member on 21 June 2021.</p> more like this
answering member constituency Charnwood more like this
answering member printed Edward Argar more like this
question first answered
less than 2021-06-23T13:25:47.34Zmore like thismore than 2021-06-23T13:25:47.34Z
answering member
4362
label Biography information for Edward Argar more like this
tabling member
1538
label Biography information for Rosie Cooper more like this